BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31625769)

  • 1. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
    Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
    Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
    Jacobs I; Petersel D; Isakov L; Lula S; Lea Sewell K
    BioDrugs; 2016 Dec; 30(6):525-570. PubMed ID: 27885553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
    Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
    J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
    Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of biosimilars for rheumatoid arthritis.
    Conran CA; Moreland LW
    Curr Opin Pharmacol; 2022 Jun; 64():102234. PubMed ID: 35552095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in Dermatology - theory becomes reality.
    Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.